ARCHIVES

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 35 | September 27, 2002

Download PDF Visit The Full Archive

Related Articles

ACS Asks Reagan To Back Stronger Cigarette Warning

April 2, 1982

NIH Plans Conference On DCIS Diagnosis, Management

July 17, 2009

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

More Concept Approvals By DCPC Board

May 18, 1984

Presidents’ FY93 Budget Holds NCI To $2 Billion, Gives NIH 5% Increase; Coalition ‘Disapionted’

February 7, 1992

Low-Income Women Lack Mammography Access: Survey

May 14, 1993